Inflammatory Myopathy Occurring Shortly After Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination

Two Case Reports

Kritchai Vutipongsatorn; Anthony Isaacs; Ziad Farah


J Med Case Reports. 2022;16(57) 

In This Article


Coronavirus disease 2019 (COVID-19) is a disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that was first identified in Wuhan, China, in December 2019. Since then, COVID-19 has become a global pandemic, infecting over 259 million people and causing over 5 million deaths worldwide.[1] Several vaccines against SARS-CoV-2 have been developed and approved, including the novel messenger ribonucleic acid (mRNA) vaccines. Studies have shown that these vaccines are safe, highly effective, and can avert serious symptoms of severe COVID-19, and reduce hospitalizations and mortality.[2] In this case series, we describe two patients who developed idiopathic inflammatory myopathy (IIM) within 48 hours of receiving the BNT162b2 vaccine.